Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR-NBL2: Induction, Consolidation, and Radiotherapy in High-Risk Neuroblastoma
NCT04221035Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Nov 2019
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 20
01
Overview
A Phase 3 trial of Dinutuximab beta, thiotepa in neuroblastoma, sponsored by Gustave Roussy. Started Nov 2019; status: recruiting.
02
Drugs
Dinutuximab betathiotepa
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04221035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221035.